Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-06-2017 | Original Article

Serious fungal infections in Canada

Authors: S. F. Dufresne, D. C. Cole, D. W. Denning, D. C. Sheppard

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 6/2017

Abstract

There are currently no nationwide epidemiological data on fungal infections in Canada. We estimated the burden of serious fungal diseases using literature review and modeling, as per a methodology previously described by the LIFE program (http://www.LIFE-worldwide.org). Among the population of Canada (35.5 million in 2014), it was estimated that approximately 1.8% are affected by a serious fungal infection. Recurrent vulvovaginal candidiasis, severe asthma with fungal sensitization, and allergic bronchopulmonary aspergillosis are the most frequent infections, with population prevalences of 498,688 (1403/100,000), 73,344 (206/100,000), and 61,854 (174/100,000) cases, respectively. Over 3000 invasive fungal infections are estimated to occur annually, with incidences of 2068 cases (5.8/100,000) of invasive candidiasis, 566 cases (1.6/100,000) of invasive aspergillosis, 252 cases (0.71/100,000) of Pneumocystis pneumonia, 99 cases (0.28/100,000) of endemic mycoses, and 63 cases (0.18/100,000) of cryptococcosis. These estimates warrant validation through more formal epidemiological studies in Canada.

Nicolle L, Rotstein C, Bourgault A, St-Germain G, Garber G; Canadian Infectious Diseases Society Invasive Fungal Registry (1998) Invasive fungal infections in Canada from 1992 to 1994. Can J Infect Dis 9(6):347–352CrossRefPubMedPubMedCentral

Rodriguez-Tudela JL, Alastruey-Izquierdo A, Gago S, Cuenca-Estrella M, León C, Miro JM, Nuñez Boluda A, Ruiz Camps I, Sole A, Denning DW; University of Manchester in association with the LIFE program (2015) Burden of serious fungal infections in Spain. Clin Microbiol Infect 21(2):183–189. doi:10.1016/j.cmi.2014.07.013 CrossRefPubMed

Ruhnke M, Groll AH, Mayser P, Ullmann AJ, Mendling W, Hof H, Denning DW; University of Manchester in association with the LIFE program (2015) Estimated burden of fungal infections in Germany. Mycoses 58(Suppl 5):22–28. doi:10.1111/myc.12392 CrossRefPubMed

Statistics Canada. Table 051-0001. Estimates of population, by age group and sex for July 1, Canada, provinces and territories, annual (persons unless otherwise noted). CANSIM (database)

Statistics Canada. Table 105-0502. Health indicator profile, two year period estimates, by age group and sex, Canada, provinces, territories, health regions (2013 boundaries) and peer groups, occasional. CANSIM (database)

Canadian Cancer Society (2015) Acute myelogenous leukemia statistics. Available online at: http://www.cancer.ca/en/cancer-information/cancer-type/leukemia-acute-myelogenous-aml/statistics/?region=on. Accessed 10 Apr 2015

Canadian Cancer Society’s AdvisoryCommittee on Cancer Statistics (2015) Canadian Cancer Statistics. Canadian Cancer Society, Toronto, Ontario

Canadian Institute for Health Information (CIHI) (2014) Canadian organ replacement register annual report: treatment of end-stage organ failure in Canada, 2003 to 2012. CIHI, Ottawa, Ontario

Organisation for Economic Co-operation and Development (OECD) (2013) Health at a glance 2013: OECD indicators (2013). OECD Publishing

10.

Public Health Agency of Canada (2014) HIV and AIDS in Canada: surveillance report to December 31, 2013. Minister of Public Works and Government Services Canada, Ottawa, Ontario

11.

World Health Organization (WHO) (2014) Tuberculosis country profiles: Canada. Available online at: https://extranet.who.int/sree/Reports?op=Replet&name=%2FWHO_HQ_Reports%2FG2%2FPROD%2FEXT%2FTBCountryProfile&ISO2=CA&LAN=EN&outtype=html. Accessed 16 Aug 2016

12.

Cystic Fibrosis Canada (2015) The Canadian Cystic Fibrosis Registry: 2013 annual report

13.

Laupland KB, Gregson DB, Church DL, Ross T, Elsayed S (2005) Invasive Candida species infections: a 5 year population-based assessment. J Antimicrob Chemother 56(3):532–537. doi:10.1093/jac/dki258 CrossRefPubMed

14.

St-Germain G, Laverdière M, Pelletier R, René P, Bourgault AM, Lemieux C, Libman M (2008) Epidemiology and antifungal susceptibility of bloodstream Candida isolates in Quebec: Report on 453 cases between 2003 and 2005. Can J Infect Dis Med Microbiol 19(1):55–62PubMedPubMedCentral

15.

Clancy CJ, Nguyen MH (2013) Finding the “missing 50%” of invasive candidiasis: how nonculture diagnostics will improve understanding of disease spectrum and transform patient care. Clin Infect Dis 56(9):1284–1292. doi:10.1093/cid/cit006 CrossRefPubMed

16.

Barkati S, Dufresne SF, Bélanger S, Vadnais B, Bergeron J, Labbé AC, Laverdière M (2014) Incidence of invasive aspergillosis following remission-induction chemotherapy for acute leukemia: a retrospective cohort study in a single Canadian tertiary care centre. CMAJ Open 2(2):E86–E93. doi:10.9778/cmajo.20130062 CrossRefPubMedPubMedCentral

17.

Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, Pastore D, Picardi M, Bonini A, Chierichini A, Fanci R, Caramatti C, Invernizzi R, Mattei D, Mitra ME, Melillo L, Aversa F, Van Lint MT, Falcucci P, Valentini CG, Girmenia C, Nosari A (2006) The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica 91(8):1068–1075PubMed

18.

Steinbach WJ, Marr KA, Anaissie EJ, Azie N, Quan SP, Meier-Kriesche HU, Apewokin S, Horn DL (2012) Clinical epidemiology of 960 patients with invasive aspergillosis from the PATH Alliance registry. J Infect 65(5):453–464. doi:10.1016/j.jinf.2012.08.003 CrossRefPubMed

19.

Pappas PG, Alexander BD, Andes DR, Hadley S, Kauffman CA, Freifeld A, Anaissie EJ, Brumble LM, Herwaldt L, Ito J, Kontoyiannis DP, Lyon GM, Marr KA, Morrison VA, Park BJ, Patterson TF, Perl TM, Oster RA, Schuster MG, Walker R, Walsh TJ, Wannemuehler KA, Chiller TM (2010) Invasive fungal infections among organ transplant recipients: results of the Transplant-Associated Infection Surveillance Network (TRANSNET). Clin Infect Dis 50(8):1101–1111. doi:10.1086/651262 CrossRefPubMed

20.

Corzo-León DE, Satlin MJ, Soave R, Shore TB, Schuetz AN, Jacobs SE, Walsh TJ (2015) Epidemiology and outcomes of invasive fungal infections in allogeneic haematopoietic stem cell transplant recipients in the era of antifungal prophylaxis: a single-centre study with focus on emerging pathogens. Mycoses 58(6):325–336. doi:10.1111/myc.12318 CrossRefPubMed

21.

Harrison N, Mitterbauer M, Tobudic S, Kalhs P, Rabitsch W, Greinix H, Burgmann H, Willinger B, Presterl E, Forstner C (2015) Incidence and characteristics of invasive fungal diseases in allogeneic hematopoietic stem cell transplant recipients: a retrospective cohort study. BMC Infect Dis 15:584. doi:10.1186/s12879-015-1329-6 CrossRefPubMedPubMedCentral

22.

Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Baden LR, Gersten ID, Mendizabal AM, Leather HL, Confer DL, Maziarz RT, Stadtmauer EA, Bolaños-Meade J, Brown J, Dipersio JF, Boeckh M, Marr KA; Blood and Marrow Transplant Clinical Trials Network (2010) Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation. Blood 116(24):5111–5118. doi:10.1182/blood-2010-02-268151 CrossRefPubMedPubMedCentral

23.

Montesinos P, Rodríguez-Veiga R, Boluda B, Martínez-Cuadrón D, Cano I, Lancharro A, Sanz J, Arilla MJ, López-Chuliá F, Navarro I, Lorenzo I, Salavert M, Pemán J, Calvillo P, Martínez J, Carpio N, Jarque I, Sanz GF, Sanz MA (2015) Incidence and risk factors of post-engraftment invasive fungal disease in adult allogeneic hematopoietic stem cell transplant recipients receiving oral azoles prophylaxis. Bone Marrow Transplant 50(11):1465–1472. doi:10.1038/bmt.2015.181 CrossRefPubMed

24.

Kontoyiannis DP, Marr KA, Park BJ, Alexander BD, Anaissie EJ, Walsh TJ, Ito J, Andes DR, Baddley JW, Brown JM, Brumble LM, Freifeld AG, Hadley S, Herwaldt LA, Kauffman CA, Knapp K, Lyon GM, Morrison VA, Papanicolaou G, Patterson TF, Perl TM, Schuster MG, Walker R, Wannemuehler KA, Wingard JR, Chiller TM, Pappas PG (2010) Prospective surveillance for invasive fungal infections in hematopoietic stem cell transplant recipients, 2001–2006: overview of the Transplant-Associated Infection Surveillance Network (TRANSNET) Database. Clin Infect Dis 50(8):1091–1100. doi:10.1086/651263 CrossRefPubMed

25.

Guinea J, Torres-Narbona M, Gijón P, Muñoz P, Pozo F, Peláez T, de Miguel J, Bouza E (2010) Pulmonary aspergillosis in patients with chronic obstructive pulmonary disease: incidence, risk factors, and outcome. Clin Microbiol Infect 16(7):870–877. doi:10.1111/j.1469-0691.2009.03015.x CrossRefPubMed

26.

Kidd SE, Hagen F, Tscharke RL, Huynh M, Bartlett KH, Fyfe M, Macdougall L, Boekhout T, Kwon-Chung KJ, Meyer W (2004) A rare genotype of Cryptococcus gattii caused the cryptococcosis outbreak on Vancouver Island (British Columbia, Canada). Proc Natl Acad Sci U S A 101(49):17258–17263. doi:10.1073/pnas.0402981101 CrossRefPubMedPubMedCentral

27.

BC Centre for Disease Control (2014) British Columbia Annual Summary of Reportable Diseases 2013. Communicable Disease Prevention and Control Services (CDPACS), Provincial Health Services Authority Vancouver, British Columbia

28.

Dalcin D, Ahmed SZ (2015) Blastomycosis in northwestern Ontario, 2004 to 2014. Can J Infect Dis Med Microbiol 26(5):259–262PubMedPubMedCentral

29.

Morris SK, Brophy J, Richardson SE, Summerbell R, Parkin PC, Jamieson F, Limerick B, Wiebe L, Ford-Jones EL (2006) Blastomycosis in Ontario, 1994–2003. Emerg Infect Dis 12(2):274–279. doi:10.3201/eid1202.050849 CrossRefPubMedPubMedCentral

30.

Litvinov IV, St-Germain G, Pelletier R, Paradis M, Sheppard DC (2013) Endemic human blastomycosis in Quebec, Canada, 1988–2011. Epidemiol Infect 141(6):1143–1147. doi:10.1017/s0950268812001860 CrossRefPubMed

31.

Government of Manitoba (2014) Manitoba Annual Summary of Communicable Diseases 2013. Epidemiology & Surveillance, Public Health Branch, Public Health and Primary Health Care Division, Manitoba Health, Healthy Living and Seniors

32.

Guy R, Roy O, Poupart G, Panisset M (1949) Histoplasmin sensitivity; preliminary observations in a group of school children in the Province of Quebec. Can J Public Health 40(2):68–71PubMed

33.

Leznoff A, Frank H, Taussig A, Brandt JL (1969) The focal distribution of histoplasmosis in Montreal. Can J Public Health 60(8):321–325PubMed

34.

MacEachern EJ, McDonald JC (1971) Histoplasmin sensitivity in McGill University students. Can J Public Health 62(5):415–422PubMed

35.

Sekhon AS, Isaac-Renton J, Dixon JM, Stein L, Sims HV (1991) Review of human and animal cases of coccidioidomycosis diagnosed in Canada. Mycopathologia 113(1):1–10CrossRefPubMed

36.

Denning DW, Pleuvry A, Cole DC (2011) Global burden of chronic pulmonary aspergillosis as a sequel to pulmonary tuberculosis. Bull World Health Organ 89(12):864–872. doi:10.2471/blt.11.089441 CrossRefPubMedPubMedCentral

37.

Smith NL, Denning DW (2011) Underlying conditions in chronic pulmonary aspergillosis including simple aspergilloma. Eur Respir J 37(4):865–872. doi:10.1183/09031936.00054810 CrossRefPubMed

38.

Denning DW, Pleuvry A, Cole DC (2013) Global burden of allergic bronchopulmonary aspergillosis with asthma and its complication chronic pulmonary aspergillosis in adults. Med Mycol 51(4):361–370. doi:10.3109/13693786.2012.738312 CrossRefPubMed

39.

Baxter CG, Dunn G, Jones AM, Webb K, Gore R, Richardson MD, Denning DW (2013) Novel immunologic classification of aspergillosis in adult cystic fibrosis. J Allergy Clin Immunol 132(3):560–566.e10. doi:10.1016/j.jaci.2013.04.007 CrossRefPubMed

40.

Agarwal R (2011) Severe asthma with fungal sensitization. Curr Allergy Asthma Rep 11(5):403–413. doi:10.1007/s11882-011-0217-4 CrossRefPubMed

41.

Foxman B, Muraglia R, Dietz JP, Sobel JD, Wagner J (2013) Prevalence of recurrent vulvovaginal candidiasis in 5 European countries and the United States: results from an internet panel survey. J Low Genit Tract Dis 17(3):340–345. doi:10.1097/LGT.0b013e318273e8cf CrossRefPubMed

42.

Lalla RV, Latortue MC, Hong CH, Ariyawardana A, D’Amato-Palumbo S, Fischer DJ, Martof A, Nicolatou-Galitis O, Patton LL, Elting LS, Spijkervet FK, Brennan MT; Fungal Infections Section, Oral Care Study Group, Multinational Association of Supportive Care in Cancer (MASCC)/International Society of Oral Oncology (ISOO) (2010) A systematic review of oral fungal infections in patients receiving cancer therapy. Support Care Cancer 18(8):985–992. doi:10.1007/s00520-010-0892-z CrossRefPubMedPubMedCentral

43.

Matee MI, Scheutz F, Moshy J (2000) Occurrence of oral lesions in relation to clinical and immunological status among HIV-infected adult Tanzanians. Oral Dis 6(2):106–111CrossRefPubMed

44.

Buchacz K, Baker RK, Palella FJ Jr, Chmiel JS, Lichtenstein KA, Novak RM, Wood KC, Brooks JT; HOPS Investigators (2010) AIDS-defining opportunistic illnesses in US patients, 1994–2007: a cohort study. AIDS 24(10):1549–1559. doi:10.1097/QAD.0b013e32833a3967 CrossRefPubMed

45.

Zhu YX, Li T, Fan SR, Liu XP, Liang YH, Liu P (2016) Health-related quality of life as measured with the Short-Form 36 (SF-36) questionnaire in patients with recurrent vulvovaginal candidiasis. Health Qual Life Outcomes 14:65. doi:10.1186/s12955-016-0470-2 CrossRefPubMedPubMedCentral

46.

Fong IW (1996) Clinical and cost considerations in the pharmacotherapy of vulvovaginal candidiasis. Pharmacoeconomics 9(6):497–505CrossRefPubMed

47.

Public Health Agency of Canada (2016) Surveillance. Available online at: http://www.phac-aspc.gc.ca/surveillance-eng.php. Accessed 16 Sep 2016

48.

Azie N, Neofytos D, Pfaller M, Meier-Kriesche HU, Quan SP, Horn D (2012) The PATH (Prospective Antifungal Therapy) Alliance® registry and invasive fungal infections: update 2012. Diagn Microbiol Infect Dis 73(4):293–300. doi:10.1016/j.diagmicrobio.2012.06.012 CrossRefPubMed

49.

Haider S, Rotstein C, Horn D, Laverdiere M, Azie N (2014) The Prospective Antifungal Therapy Alliance(®) registry: A two-centre Canadian experience. Can J Infect Dis Med Microbiol 25(1):17–23PubMedPubMedCentral

Title: Serious fungal infections in Canada
Authors: S. F. Dufresne
D. C. Cole
D. W. Denning
D. C. Sheppard
Publication date: 01-06-2017
Publisher: Springer Berlin Heidelberg
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 6/2017
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-017-2922-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Serious fungal infections in Canada

Abstract

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2017

Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis

Ability to predict the development of surgical site infection in cardiac surgery using the Australian Clinical Risk Index versus the National Nosocomial Infections Surveillance-derived Risk Index

Update of the activity of telavancin against a global collection of Staphylococcus aureus causing bacteremia, including endocarditis (2011–2014)

Incidence of Cryptosporidium andersoni in diarrheal patients from southern Assam, India: a molecular approach

Serious fungal infections in Ecuador

Cost-effectiveness analysis of universal screening for carbapenemase-producing Enterobacteriaceae in hospital inpatients

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page